<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05077774</url>
  </required_header>
  <id_info>
    <org_study_id>MDT20057CON003</org_study_id>
    <nct_id>NCT05077774</nct_id>
  </id_info>
  <brief_title>Harmony TPV Post-Approval Study</brief_title>
  <official_title>Harmony TPV Post-Approval Study (Harmony PAS2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the functionality of transcatheter implantation&#xD;
      of the Medtronic Harmony Transcatheter Pulmonary Valve (TPV) achieved by real-world&#xD;
      implanters.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2021</start_date>
  <completion_date type="Anticipated">May 2034</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects without valve intervention and with acceptable hemodynamic function composite at 6 months as defined by:</measure>
    <time_frame>6 months</time_frame>
    <description>Mean RVOT gradient as measured by continuous-wave Doppler echocardiography â‰¤40 mmHg AND&#xD;
Pulmonary regurgitant fraction as measured by CMR &lt;20%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects free from all-cause mortality at 6-months</measure>
    <time_frame>6 months</time_frame>
    <description>Described by Kaplan-Meier statistics at 6-months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects free from reoperation at 6-months</measure>
    <time_frame>6 months</time_frame>
    <description>Described by Kaplan-Meier statistics at 6-months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects free from catheter reintervention at 6-months</measure>
    <time_frame>6 months</time_frame>
    <description>Described by Kaplan-Meier statistics at 6-months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects free from TPV dysfunction at 6-months</measure>
    <time_frame>6 months</time_frame>
    <description>Described by Kaplan-Meier statistics at 6-months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with procedure success at 30-days</measure>
    <time_frame>30-days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with serious procedure- and device-related adverse events at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Also described with Kaplan-Meier method for AEs of clinical interest.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Congenital Heart Disease</condition>
  <condition>Tetrology of Fallot</condition>
  <condition>RVOT Anomaly</condition>
  <condition>Pulmonary Regurgitation</condition>
  <arm_group>
    <arm_group_label>Harmony TPV System</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intervention Device: Harmony Transcatheter Pulmonary Valves and Delivery System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Harmony TPV System</intervention_name>
    <description>Harmony Transcatheter Pulmonary Valve (sizes 22 mm and 25 mm) and Harmony Delivery Catheter System (DCS)</description>
    <arm_group_label>Harmony TPV System</arm_group_label>
    <other_name>Model Numbers: HARMONY-22, HARMONY-25, and HARMONY-DCS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient eligible to receive the Harmony TPV, meeting the indications for use criteria&#xD;
             per current geography-specific device labeling at time of study enrollment&#xD;
&#xD;
          -  Patient (or patient's legally authorized representative) is willing to consent to&#xD;
             participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anatomy unable to accommodate a 25 Fr delivery catheter system&#xD;
&#xD;
          -  Obstruction of the central veins&#xD;
&#xD;
          -  Clinical or biological signs of infection including active endocarditis&#xD;
&#xD;
          -  Planned concomitant branch pulmonary artery stenting at time of implant&#xD;
&#xD;
          -  Positive pregnancy test at baseline (prior to CT angiography and again prior to&#xD;
             implant procedure) in female subjects of childbearing potential&#xD;
&#xD;
          -  Patients with right ventricular outflow tract obstruction (RVOTO) lesions surgically&#xD;
             treated with an RV-PA conduit implant&#xD;
&#xD;
          -  A major or progressive non-cardiac disease (e.g. liver failure, renal failure, cancer)&#xD;
             that results in a life expectancy of less than one year&#xD;
&#xD;
          -  Planned implantation of the Harmony TPV in the left heart&#xD;
&#xD;
          -  Known allergy to aspirin, heparin, or nickel&#xD;
&#xD;
          -  Echocardiographic evidence of intracardiac mass, thrombus, or vegetation&#xD;
&#xD;
          -  Pre-existing prosthetic heart valve or prosthetic ring in any position&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Balzer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Louis Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle Vanney</last_name>
    <phone>763-514-4000</phone>
    <email>RS.HarmonyPAS2@medtronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Harmony Clinical Study Central Email</last_name>
    <email>RS.HarmonyPAS2@medtronic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UPMC Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryan Goldstein, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D. Scott Lim, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 30, 2021</study_first_submitted>
  <study_first_submitted_qc>October 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
    <mesh_term>Tetralogy of Fallot</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

